leadf
logo-loader
viewVolitionRx

VolitionRx closes $13.8M public offering to fund product development and clinical studies

The Texas-based company is developing a coronavirus triage test to predict the likelihood that a positive individual will develop complications

VolitionRx - VolitionRx closes $13.8M public offering to fund product development and clinical studies
VolitionRx intends to use the money from the offering for continued product development, clinical studies, product commercialization, working capital, and potential strategic acquisitions

VolitionRx Limited (NYSEAMERICAN:VNRX) has announced the closing of its previously announced public offering to raise $13.8 million to support the epigenetics company’s continued product development and clinical studies.

In a statement, the Austin, Texas-based company said it offered 5,019,750 shares, including the exercise in full of the overallotment option, at a price of $2.75 per share for total gross proceeds of $13.8 million, before deducting underwriting discounts. All the shares sold were offered by the company.

READ: VolitionRx actively developing coronavirus (COVID-19) triage test using its proprietary Nu.QTM platform

The company intends to use the money from the offering, that closed on May 22, for continued product development, clinical studies, product commercialization, working capital, and potential strategic acquisitions.

The funds come at a time when the company is actively developing a coronavirus (COVID-19) triage test using its flagship Nu.Q test (normally used to detect cancer biomarkers) to predict the likelihood that a positive individual will develop complications and severe disease.

It recently conducted a proof of concept study involving 34 COVID-19 positive subjects and 50 control subjects that produced promising results. And preliminary studies of infected patients are now underway in hospitals in Belgium and Germany, with results expected in the second quarter.

Volition is developing easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that disease is present.

National Securities Corporation, a wholly-owned subsidiary of National Holdings Corporation (NASDAQ: NHLD), acted as sole book-running manager for the offering. The Benchmark Company and Maxim Group acted as financial advisors in the offering.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: VolitionRx

Price: 3.03 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $145.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx hosts virtual capital markets day event to discuss upcoming...

VolitionRx Limited (NYSE AMERICAN: VNRX) CEO Cameron Reynolds the Austin, Texas-based epigenetics company hosted a virtual capital markets day event on Tuesday, October 20, 2020. Reynolds says the presentation focused on new data, and the launch and commercial roll out of the company's first...

1 week, 1 day ago

2 min read